Samuel Singer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2257269/publications.pdf

Version: 2024-02-01

211 papers

37,177 citations

87 h-index 188 g-index

215 all docs

215 docs citations

215 times ranked

29551 citing authors

#	Article	IF	CITATIONS
1	Percutaneous Cryoablation Provides Disease Control for Extra-Abdominal Desmoid-Type Fibromatosis Comparable with Surgical Resection. Annals of Surgical Oncology, 2022, 29, 640-648.	1.5	17
2	Lowâ€grade endometrial stromal sarcomaâ€like tumors in male with <scp><i>JAZF1</i></scp> gene fusions. Genes Chromosomes and Cancer, 2022, 61, 63-70.	2.8	2
3	A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma. Clinical Cancer Research, 2022, 28, 175-186.	7.0	4
4	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 2022, 40, 997-1008.	1.6	13
5	ASO Visual Abstract: Enhanced PAtient Clinical Streamlining (EPACS)—Quality Initiative to Improve Healthcare for New Surgical Outpatient Visits. Annals of Surgical Oncology, 2022, 29, 1805-1806.	1.5	O
6	Enhanced PAtient Clinical Streamlining (EPACS): Quality Initiative to Improve Healthcare for New Surgical Outpatient Visits. Annals of Surgical Oncology, 2022, 29, 1789-1796.	1.5	1
7	Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2022, 28, 1507-1517.	7.0	3
8	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	28.9	223
9	<i><scp>FGFR2</scp>::<scp>TACC2</scp></i> fusion as a novel <scp>KIT</scp> â€independent mechanism of targeted therapy failure in a multidrugâ€resistant gastrointestinal stromal tumor. Genes Chromosomes and Cancer, 2022, 61, 412-419.	2.8	4
10	Comprehensive genomic profiling of EWSR1/FUS::CREB translocation-associated tumors uncovers prognostically significant recurrent genetic alterations and methylation-transcriptional correlates. Modern Pathology, 2022, 35, 1055-1065.	5 . 5	13
11	Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center., 2022, 10, e004149.		20
12	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nature Communications, 2022, 13, .	12.8	63
13	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nature Communications, 2022, 13, .	12.8	51
14	Presence of immune infiltrates, increased expression of transposable elements, and viral response pathways in sarcoma associate with response to checkpoint inhibition Journal of Clinical Oncology, 2022, 40, 11510-11510.	1.6	0
15	Femoral Fracture in Primary Soft Tissue Sarcoma Treated with Intensity-Modulated Radiation Therapy with and Without Dose Constraints. Annals of Surgical Oncology, 2021, 28, 2700-2704.	1.5	3
16	Histologic Subtype Defines the Risk and Kinetics of Recurrence and Death for Primary Extremity/Truncal Liposarcoma. Annals of Surgery, 2021, 273, 1189-1196.	4.2	11
17	The Oncolytic Activity of Myxoma Virus against Soft Tissue Sarcoma Is Mediated by the Overexpression of Ribonucleotide Reductase. Clinical Medicine Insights: Oncology, 2021, 15, 117955492199306.	1.3	2
18	A phase 1b study of avelumab plus DCC-3014, a potent and selective inhibitor of colony stimulating factor 1 receptor (CSF1R), in patients with advanced high-grade sarcoma. Journal of Clinical Oncology, 2021, 39, 11549-11549.	1.6	7

#	Article	IF	Citations
19	Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot. Cancer Medicine, 2021, 10, 4221-4227.	2.8	8
20	Radiation Therapy in Primary Soft Tissue Sarcoma of the Superficial Trunk. Annals of Surgical Oncology, 2021, , 1.	1.5	0
21	Association of MRI T2 Signal Intensity With Desmoid Tumor Progression During Active Observation. Annals of Surgery, 2020, 271, 748-755.	4.2	40
22	Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. Modern Pathology, 2020, 33, 591-602.	5 . 5	87
23	Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. JCO Precision Oncology, 2020, 4, 1350-1360.	3.0	18
24	Statistical Assessment of Depth Normalization for Small RNA Sequencing. JCO Clinical Cancer Informatics, 2020, 4, 567-582.	2.1	8
25	Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival. Cancer Research, 2020, 80, 2461-2471.	0.9	22
26	A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST) Journal of Clinical Oncology, 2020, 38, 11508-11508.	1.6	10
27	A phase Ib study of BCJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. Investigational New Drugs, 2019, 37, 282-290.	2.6	32
28	GLI1-amplifications expand the spectrum of soft tissue neoplasms defined by GLI1 gene fusions. Modern Pathology, 2019, 32, 1617-1626.	5 . 5	70
29	miR-193b regulates tumorigenesis in liposarcoma cells via PDGFR, TGF \hat{l}^2 , and Wnt signaling. Scientific Reports, 2019, 9, 3197.	3.3	20
30	Femoral Fracture in Primary Soft-Tissue Sarcoma of the Thigh and Groin Treated with Intensity-Modulated Radiation Therapy: Observed versus Expected Risk. Annals of Surgical Oncology, 2019, 26, 1326-1331.	1.5	20
31	Yield of Colonoscopy in Identification of Newly Diagnosed Desmoid-Type Fibromatosis with Underlying Familial Adenomatous Polyposis. Annals of Surgical Oncology, 2019, 26, 765-771.	1.5	12
32	Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma Journal of Clinical Oncology, 2019, 37, 11004-11004.	1.6	44
33	A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma Journal of Clinical Oncology, 2019, 37, 11049-11049.	1.6	12
34	Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors. Annals of Surgery, 2018, 268, 296-302.	4.2	58
35	PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence. Oncogene, 2018, 37, 5066-5078.	5.9	38
36	A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic sarcoma Journal of Clinical Oncology, 2018, 36, 11516-11516.	1.6	6

#	Article	lF	Citations
37	Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 319-330.e1.	0.8	96
38	Treatment Recommendations for Retroperitoneal Liposarcoma. International Journal of Radiation Oncology Biology Physics, 2017, 98, 271.	0.8	3
39	BCOR upregulation in a poorly differentiated synovial sarcoma with ⟨i⟩SS18L1â€SSX1⟨ i⟩ fusion—A pathologic and molecular pitfall. Genes Chromosomes and Cancer, 2017, 56, 296-302.	2.8	30
40	Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome. American Journal of Surgical Pathology, 2017, 41, 941-949.	3.7	278
41	SKP2 Activation by Thyroid Hormone Receptor \hat{I}^2 2 Bypasses Rb-Dependent Proliferation in Rb-Deficient Cells. Cancer Research, 2017, 77, 6838-6850.	0.9	8
42	Size and Location are the Most Important Risk Factors for Malignant Behavior in Resected Solitary Fibrous Tumors. Annals of Surgical Oncology, 2017, 24, 3865-3871.	1.5	69
43	miR-193b–Regulated Signaling Networks Serve as Tumor Suppressors in Liposarcoma and Promote Adipogenesis in Adipose-Derived Stem Cells. Cancer Research, 2017, 77, 5728-5740.	0.9	50
44	ATRX is a regulator of therapy induced senescence in human cells. Nature Communications, 2017, 8, 386.	12.8	59
45	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell, 2017, 171, 950-965.e28.	28.9	738
46	The clinical impact of performing routine next generation sequencing (NGS) in gastrointestinal stromal tumors (GIST) Journal of Clinical Oncology, 2017, 35, 11010-11010.	1.6	3
47	Integrin-alpha10 drives tumorigenesis in sarcoma. Oncoscience, 2017, 4, 31-32.	2.2	3
48	A phase Ib study of BGJ398 in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST) Journal of Clinical Oncology, 2017, 35, 11039-11039.	1.6	0
49	Histology-based Classification Predicts Pattern of Recurrence and Improves Risk Stratification in Primary Retroperitoneal Sarcoma. Annals of Surgery, 2016, 263, 593-600.	4.2	238
50	Recurrent CIC Gene Abnormalities in Angiosarcomas. American Journal of Surgical Pathology, 2016, 40, 645-655.	3.7	157
51	Targeted exome sequencing profiles genetic alterations in leiomyosarcoma. Genes Chromosomes and Cancer, 2016, 55, 124-130.	2.8	38
52	Empirical insights into the stochasticity of small RNA sequencing. Scientific Reports, 2016, 6, 24061.	3.3	5
53	Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With <i>CDK4</i> Inhibitor Palbociclib. JAMA Oncology, 2016, 2, 937.	7.1	241
54	Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma. Cancer Research, 2016, 76, 6095-6106.	0.9	30

#	Article	IF	Citations
55	Integrin- $\hat{l}\pm 10$ Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma. Cancer Discovery, 2016, 6, 1148-1165.	9.4	62
56	Optimal Percent Myxoid Component to Predict Outcome in High-Grade Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma. Annals of Surgical Oncology, 2016, 23, 818-825.	1.5	33
57	Near universal detection of alterations in <scp><i>CTNNB1</i></scp> and <scp>Wnt</scp> pathway regulators in desmoidâ€type fibromatosis by wholeâ€exome sequencing and genomic analysis. Genes Chromosomes and Cancer, 2015, 54, 606-615.	2.8	138
58	Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications. American Journal of Surgical Pathology, 2015, 39, 813-825.	3.7	177
59	Soft tissue sarcoma of the head & mp; neck: Nomogram validation and analysis of staging systems. Journal of Surgical Oncology, 2015, 111, 690-695.	1.7	19
60	Application of Molecular Biology to Individualize Therapy for Patients with Liposarcoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 213-218.	3.8	18
61	Comparison of Perioperative Radiation Therapy and Surgery Versus Surgery Alone in 204 Patients With Primary Retroperitoneal Sarcoma. Annals of Surgery, 2015, 262, 156-162.	4.2	64
62	Posterior Reversible Encephalopathy Syndrome in Patients With Cancer. Oncologist, 2015, 20, 806-811.	3.7	88
63	Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging. Science Translational Medicine, 2015, 7, 271ra7.	12.4	236
64	A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas. Oncologist, 2015, 20, 1245-1246.	3.7	25
65	Novel oncogene and tumor suppressor mutations in <i>KIT</i> and <i>PDGFRA</i> wild type gastrointestinal stromal tumors revealed by next generation sequencing. Genes Chromosomes and Cancer, 2015, 54, 177-184.	2.8	28
66	MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget, 2015, 6, 8226-8243.	1.8	107
67	A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nature Genetics, 2014, 46, 595-600.	21.4	152
68	Lessons Learned From the Study of 10,000 Patients With Soft Tissue Sarcoma. Annals of Surgery, 2014, 260, 416-422.	4.2	321
69	Novel <i>ZC3H7Bâ€BCOR</i> , <i>MEAF6â€PHF1</i> , and <i>EPC1â€PHF1</i> fusions in ossifying fibromyxoid tumors— molecular characterization shows genetic overlap with endometrial stromal sarcoma. Genes Chromosomes and Cancer, 2014, 53, 183-193.	2.8	145
70	PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nature Genetics, 2014, 46, 1227-1232.	21.4	472
71	Consistent <i>SMARCB1</i> homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material. Genes Chromosomes and Cancer, 2014, 53, 475-486.	2.8	120
72	Cryptogenic Subtype Predicts Reduced Survival Among Cancer Patients With Ischemic Stroke. Stroke, 2014, 45, 2292-2297.	2.0	80

#	Article	IF	CITATIONS
73	Comparison of Local Recurrence With Conventional and Intensity-Modulated Radiation Therapy for Primary Soft-Tissue Sarcomas of the Extremity. Journal of Clinical Oncology, 2014, 32, 3236-3241.	1.6	125
74	Recurrent thromboembolic events after ischemic stroke in patients with cancer. Neurology, 2014, 83, 26-33.	1.1	144
75	Extraskeletal myxoid chondrosarcoma with non–EWSR1-NR4A3 variant fusions correlate with rhabdoid phenotype and high-grade morphology. Human Pathology, 2014, 45, 1084-1091.	2.0	83
76	Toward Better Soft Tissue Sarcoma Staging: Building on American Joint Committee on Cancer Staging Systems Versions 6 and 7. Annals of Surgical Oncology, 2013, 20, 3377-3383.	1.5	52
77	Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced <i>CDK4</i> -Amplified Well-Differentiated or Dedifferentiated Liposarcoma. Journal of Clinical Oncology, 2013, 31, 2024-2028.	1.6	370
78	Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nature Genetics, 2013, 45, 180-185.	21.4	662
79	Oncologic Outcomes of Sporadic, Neurofibromatosis-Associated, and Radiation-Induced Malignant Peripheral Nerve Sheath Tumors. Annals of Surgical Oncology, 2013, 20, 66-72.	1.5	104
80	Predictors of Survival and Recurrence in Primary Leiomyosarcoma. Annals of Surgical Oncology, 2013, 20, 1851-1857.	1.5	128
81	Novel MIR143â€NOTCH fusions in benign and malignant glomus tumors. Genes Chromosomes and Cancer, 2013, 52, 1075-1087.	2.8	138
82	Pediatric and Adolescent Synovial Sarcoma: Multivariate Analysis of Prognostic Factors and Survival Outcomes. Annals of Surgical Oncology, 2013, 20, 73-79.	1.5	38
83	Adult Rhabdomyosarcoma Survival Improved With Treatment on Multimodality Protocols. International Journal of Radiation Oncology Biology Physics, 2013, 86, 58-63.	0.8	68
84	Blood Neutrophil-to-Lymphocyte Ratio is Prognostic in Gastrointestinal Stromal Tumor. Annals of Surgical Oncology, 2013, 20, 593-599.	1.5	64
85	An Empirical Evaluation of normalization Methods for MicroRNA Arrays in a Liposarcoma Study. Cancer Informatics, 2013, 12, CIN.S11384.	1.9	6
86	Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets. Science Signaling, 2013, 6, ra85.	3.6	97
87	A Prognostic Nomogram for Prediction of Recurrence in Desmoid Fibromatosis. Annals of Surgery, 2013, 258, 347-353.	4.2	222
88	Poor prognostic features in angiosarcoma: A single institution retrospective study of 324 patients Journal of Clinical Oncology, 2013, 31, 10580-10580.	1.6	0
89	Association of perioperative radiation therapy with outcome in 204 patients with primary retroperitoneal sarcoma: A two-institution study Journal of Clinical Oncology, 2013, 31, 10520-10520.	1.6	0
90	The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial. Clinical Cancer Research, 2012, 18, 2638-2647.	7.0	85

#	Article	IF	Citations
91	Prognostic Factors and Survival in Pediatric and Adolescent Liposarcoma. Sarcoma, 2012, 2012, 1-6.	1.3	17
92	Copy Number Losses Define Subgroups of Dedifferentiated Liposarcoma with Poor Prognosis and Genomic Instability. Clinical Cancer Research, 2012, 18, 1334-1340.	7.0	59
93	A Postoperative Nomogram for Local Recurrence Risk in Extremity Soft Tissue Sarcomas After Limb-Sparing Surgery Without Adjuvant Radiation. Annals of Surgery, 2012, 255, 343-347.	4.2	135
94	SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors. BMC Cancer, 2012, 12, 408.	2.6	54
95	Patterns of deregulation of insulin growth factor signalling pathway in paediatric and adult gastrointestinal stromal tumours. European Journal of Cancer, 2012, 48, 3215-3222.	2.8	9
96	Identification of a novel, recurrent <i>HEY1â€NCOA2</i> fusion in mesenchymal chondrosarcoma based on a genomeâ€wide screen of exonâ€level expression data. Genes Chromosomes and Cancer, 2012, 51, 127-139.	2.8	276
97	CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers. Genes Chromosomes and Cancer, 2012, 51, 186-195.	2.8	17
98	High prevalence of <i>CIC</i> fusion with doubleâ€homeobox (DUX4) transcription factors in <i>EWSR1</i> â€negative undifferentiated small blue round cell sarcomas. Genes Chromosomes and Cancer, 2012, 51, 207-218.	2.8	307
99	Restoration of C/EBPÎ \pm in dedifferentiated liposarcoma induces G2/M cell cycle arrest and apoptosis. Genes Chromosomes and Cancer, 2012, 51, 313-327.	2.8	22
100	The miRâ€17â€92 cluster and its target <i>THBS1</i> are differentially expressed in angiosarcomas dependent on <i>MYC</i> amplification. Genes Chromosomes and Cancer, 2012, 51, 569-578.	2.8	96
101	The enigma of myxofibrosarcoma of the extremity. Cancer, 2012, 118, 518-527.	4.1	58
102	Activity of sorafenib in radiation-associated breast angiosarcomas harboring MYC and FLT4 amplifications Journal of Clinical Oncology, 2012, 30, 10019-10019.	1.6	5
103	Soft Tissue Sarcomas. , 2012, , 768-782.		2
104	How well do we communicate risk? An evaluation of AJCC version 6 and 7 staging systems for soft tissue sarcomas Journal of Clinical Oncology, 2012, 30, 10001-10001.	1.6	0
105	Expression Profiling of Liposarcoma Yields a Multigene Predictor of Patient Outcome and Identifies Genes That Contribute to Liposarcomagenesis. Cancer Research, 2011, 71, 2697-2705.	0.9	86
106	Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Current Opinion in Oncology, 2011 , 23 , 373 - 378 .	2.4	203
107	Advances in sarcoma genomics and new therapeutic targets. Nature Reviews Cancer, 2011, 11, 541-557.	28.4	364
108	Small RNA Sequencing and Functional Characterization Reveals MicroRNA-143 Tumor Suppressor Activity in Liposarcoma. Cancer Research, 2011, 71, 5659-5669.	0.9	106

#	Article	IF	CITATIONS
109	Dermatofibrosarcoma protuberans (DFSP): Predictors of Recurrence and the Use of Systemic Therapy. Annals of Surgical Oncology, 2011, 18, 328-336.	1.5	88
110	Laparoscopic Versus Open Gastric Resections for Primary Gastrointestinal Stromal Tumors (GISTs): A Size-Matched Comparison. Annals of Surgical Oncology, 2011, 18, 1599-1605.	1.5	160
111	Frequent Alterations and Epigenetic Silencing of Differentiation Pathway Genes in Structurally Rearranged Liposarcomas. Cancer Discovery, 2011, 1, 587-597.	9.4	108
112	Preclinical study of treatment response in HCTâ€116 cells and xenografts with ¹ Hâ€decoupled ³¹ P MRS. NMR in Biomedicine, 2011, 24, 1159-1168.	2.8	3
113	Consistent <i>MYC</i> and <i>FLT4</i> gene amplification in radiationâ€induced angiosarcoma but not in other radiationâ€associated atypical vascular lesions. Genes Chromosomes and Cancer, 2011, 50, 25-33.	2.8	291
114	mRNA and protein levels of FUS, EWSR1, and TAF15 are upregulated in liposarcoma. Genes Chromosomes and Cancer, 2011, 50, 338-347.	2.8	31
115	A novel <i>WWTR1â€CAMTA1</i> gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes and Cancer, 2011, 50, 644-653.	2.8	445
116	Local control comparison of adjuvant brachytherapy to intensityâ€modulated radiotherapy in primary highâ€grade sarcoma of the extremity. Cancer, 2011, 117, 3229-3234.	4.1	67
117	Soft tissue sarcoma diagnosed subsequent to lymphoma is associated with prior radiotherapy and decreased survival. Cancer, 2011, 117, 4756-4763.	4.1	4
118	Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis. Clinical Cancer Research, 2011, 17, 4082-4090.	7.0	237
119	Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer, 2010, 116, 2258-2265.	4.1	163
120	Fat-free MRI based on magnetization exchange. Magnetic Resonance in Medicine, 2010, 63, 713-718.	3.0	16
121	IGF2 overâ€expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. Journal of Pathology, 2010, 221, 300-307.	4.5	78
122	The landscape of somatic copy-number alteration across human cancers. Nature, 2010, 463, 899-905.	27.8	3,331
123	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics, 2010, 42, 715-721.	21.4	642
124	SURGICAL MANAGEMENT OF SOFT TISSUE SARCOMA: HISTOLOGIC TYPE AND GRADE GUIDE SURGICAL PLANNING AND INTEGRATION OF MULTIMODALITY THERAPY. , 2010, , 1057-1069.		2
125	<i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma. Cancer Research, 2010, 70, 6891-6901.	0.9	41
126	Do Radiation-Associated Soft Tissue Sarcomas Have the Same Prognosis As Sporadic Soft Tissue Sarcomas?. Journal of Clinical Oncology, 2010, 28, 2064-2069.	1.6	250

#	Article	IF	Citations
127	A Differentiation-Based Phylogeny of Cancer Subtypes. PLoS Computational Biology, 2010, 6, e1000777.	3.2	34
128	<i>KDR</i> Activating Mutations in Human Angiosarcomas Are Sensitive to Specific Kinase Inhibitors. Cancer Research, 2009, 69, 7175-7179.	0.9	247
129	Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring <i>KIT</i> AY502-3ins Mutation: An <i>In vitro</i> Mutagenesis Screen for Drug Resistance. Clinical Cancer Research, 2009, 15, 6862-6870.	7.0	86
130	Influence of compartmental involvement on the patterns of morbidity in soft tissue sarcoma of the thigh. Cancer, 2009, 115, 149-157.	4.1	43
131	Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncology, The, 2009, 10, 1045-1052.	10.7	430
132	Predicting Outcome by Growth Rate of Locally Recurrent Retroperitoneal Liposarcoma. Annals of Surgery, 2009, 250, 977-982.	4.2	114
133	Resolution of creatine and phosphocreatine ¹ H signals in isolated human skeletal muscle using HRâ€MAS ¹ H NMR. Magnetic Resonance in Medicine, 2008, 59, 1221-1224.	3.0	16
134	A tribute to Murray F. Brennan, MD. Journal of Surgical Oncology, 2008, 97, 297-297.	1.7	0
135	Diagnosis and management of lipomatous tumors. Journal of Surgical Oncology, 2008, 97, 298-313.	1.7	191
136	Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer, 2008, 112, 608-615.	4.1	437
137	Longâ€ŧerm outcomes in extremity soft tissue sarcoma after a pathologically negative reâ€ӻesection and without radiotherapy. Cancer, 2008, 112, 2774-2779.	4.1	35
138	Extraskeletal myxoid chondrosarcoma. Cancer, 2008, 113, 3364-3371.	4.1	272
139	Novel V600E BRAF mutations in imatinibâ€naive and imatinibâ€resistant gastrointestinal stromal tumors. Genes Chromosomes and Cancer, 2008, 47, 853-859.	2.8	329
140	Why Do Patients with Low-Grade Soft Tissue Sarcoma Die?. Annals of Surgical Oncology, 2008, 15, 3550-3560.	1.5	64
141	A Developmental Model of Sarcomagenesis Defines a Differentiation-Based Classification for Liposarcomas. American Journal of Pathology, 2008, 172, 1069-1080.	3.8	65
142	Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Molecular Cancer Therapeutics, 2008, 7, 890-896.	4.1	70
143	Impact of Intensity-Modulated Radiation Therapy on Local Control in Primary Soft-Tissue Sarcoma of the Extremity. Journal of Clinical Oncology, 2008, 26, 3440-3444.	1.6	132
144	A Synovial Sarcoma-Specific Preoperative Nomogram Supports a Survival Benefit to Ifosfamide-Based Chemotherapy and Improves Risk Stratification for Patients. Clinical Cancer Research, 2008, 14, 8191-8197.	7.0	160

#	Article	IF	Citations
145	Functional Copy-Number Alterations in Cancer. PLoS ONE, 2008, 3, e3179.	2.5	142
146	Chromatographic and Electrophoretic Separations Combined with Mass Spectrometry for Metabonomics., 2007,, 149-169.		3
147	High-Resolution Magic Angle Spinning NMR Spectroscopy. , 2007, , 113-147.		8
148	Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2007, 13, 170-181.	7.0	118
149	Gene Expression Profiling of Liposarcoma Identifies Distinct Biological Types/Subtypes and Potential Therapeutic Targets in Well-Differentiated and Dedifferentiated Liposarcoma. Cancer Research, 2007, 67, 6626-6636.	0.9	217
150	Sorafenib Inhibits the Imatinib-Resistant <i>KIT T670I</i> Gatekeeper Mutation in Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2007, 13, 4874-4881.	7.0	144
151	Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor. Annals of Surgery, 2007, 245, 347-352.	4.2	273
152	Chemotherapy Is Associated With Improved Survival in Adult Patients With Primary Extremity Synovial Sarcoma. Annals of Surgery, 2007, 246, 105-113.	4.2	187
153	Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors. Annals of Surgical Oncology, 2007, 14, 134-142.	1.5	104
154	Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic softâ€issue sarcoma of the extremity. Cancer, 2007, 110, 2050-2060.	4.1	50
155	Intensity Modulated Radiation Therapy for Primary Soft Tissue Sarcoma of the Extremity: Preliminary Results. International Journal of Radiation Oncology Biology Physics, 2007, 68, 458-464.	0.8	63
156	Skeletal Metastases in Myxoid Liposarcoma: An Unusual Pattern of Distant Spread. Annals of Surgical Oncology, 2007, 14, 1507-1514.	1.5	112
157	Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. Journal of Clinical Investigation, 2007, 117, 3248-3257.	8.2	167
158	Angiogenic Profile of Soft Tissue Sarcomas Based on Analysis of Circulating Factors and Microarray Gene Expression. Journal of Surgical Research, 2006, 135, 282-290.	1.6	57
159	Subtype Specific Prognostic Nomogram for Patients With Primary Liposarcoma of the Retroperitoneum, Extremity, or Trunk. Annals of Surgery, 2006, 244, 381-391.	4.2	331
160	High-resolution MAS NMR spectroscopy detection of the spin magnetization exchange by cross-relaxation and chemical exchange in intact cell lines and human tissue specimens. Magnetic Resonance in Medicine, 2006, 55, 1246-1256.	3.0	45
161	Flavopiridol Targets c-KIT Transcription and Induces Apoptosis in Gastrointestinal Stromal Tumor Cells. Cancer Research, 2006, 66, 5858-5866.	0.9	70
162	Influence of site on the therapeutic ratio of adjuvant radiotherapy in soft-tissue sarcoma of the extremity. International Journal of Radiation Oncology Biology Physics, 2005, 63, 202-208.	0.8	62

#	Article	IF	Citations
163	Prognostic Factors for Survival in Patients With Locally Recurrent Extremity Soft Tissue Sarcomas. Annals of Surgical Oncology, 2005, 12, 228-236.	1.5	71
164	Liposarcoma subtypes: identification with computed tomography and ultrasound-guided percutaneous needle biopsy. European Radiology, 2005, 15, 383-389.	4.5	15
165	Distant metastasis in retroperitoneal dedifferentiated liposarcoma is rare and rapidly fatal: a clinicopathological study with emphasis on the low-grade myxofibrosarcoma-like pattern as an early sign of dedifferentiation. Modern Pathology, 2005, 18, 976-984.	5.5	73
166	Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation. Clinical Cancer Research, 2005, 11, 4182-4190.	7.0	768
167	Effectiveness of Palliative Procedures for Intra-Abdominal Sarcomas. Annals of Surgical Oncology, 2005, 12, 1084-1089.	1.5	29
168	Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene, 2004, 23, 3999-4006.	5.9	306
169	Evaluation of a Clinically Applicable Post-Surgical Classification System for Primary Retroperitoneal Soft-Tissue Sarcoma. Annals of Surgical Oncology, 2004, 11, 483-490.	1.5	72
170	Atypical lipomatous tumor/well-differentiated liposarcoma of the extremity and trunk wall: Importance of histological subtype with treatment recommendations. Annals of Surgical Oncology, 2004, 11, 78-84.	1.5	125
171	Water suppression without signal loss in HR-MAS 1H NMR of cells and tissues. Journal of Magnetic Resonance, 2004, 171, 143-150.	2.1	30
172	Validation of the postoperative nomogram for 12-year sarcoma-specific mortality. Cancer, 2004, 101, 2270-2275.	4.1	131
173	Multiple primary soft tissue sarcomas. Cancer, 2004, 101, 2633-2635.	4.1	40
174	The Impact of Chemotherapy on the Survival of Patients With High-grade Primary Extremity Liposarcoma. Annals of Surgery, 2004, 240, 686-697.	4.2	132
175	Reconstruction After Soft Tissue Sarcoma Resection in the Setting of Brachytherapy. Annals of Plastic Surgery, 2004, 52, 486-491.	0.9	12
176	Synovial Sarcoma. Clinical Orthopaedics and Related Research, 2004, 419, 155-161.	1.5	92
177	Synovial sarcoma: the importance of size and location for survival. Clinical Orthopaedics and Related Research, 2004, , 155-61.	1.5	43
178	Isotropic susceptibility shift under MAS: The origin of the split water resonances in 1H MAS NMR spectra of cell suspensions. Magnetic Resonance in Medicine, 2003, 50, 515-521.	3.0	26
179	<i>PDGFRA</i> Activating Mutations in Gastrointestinal Stromal Tumors. Science, 2003, 299, 708-710.	12.6	2,158
180	Vaccination With Irradiated, Autologous Melanoma Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor by Adenoviral-Mediated Gene Transfer Augments Antitumor Immunity in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2003, 21, 3343-3350.	1.6	278

#	Article	IF	Citations
181	Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 2003, 21, 4342-4349.	1.6	2,160
182	Histologic Subtype and Margin of Resection Predict Pattern of Recurrence and Survival for Retroperitoneal Liposarcoma. Annals of Surgery, 2003, 238, 358-371.	4.2	520
183	Soft tissue sarcomas of adults: state of the translational science. Clinical Cancer Research, 2003, 9, 1941-56.	7.0	224
184	Prognostic Value of <i> KIT < /i > Mutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors. Journal of Clinical Oncology, 2002, 20, 3898-3905.</i>	1.6	420
185	Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. New England Journal of Medicine, 2002, 347, 472-480.	27.0	4,018
186	Biochemical correlates of thiazolidinedione-induced adipocyte differentiation by high-resolution magic angle spinning NMR spectroscopy. Magnetic Resonance in Medicine, 2002, 48, 602-610.	3.0	33
187	PPARÎ ³ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. Journal of Clinical Investigation, 2002, 110, 923-932.	8.2	257
188	PPAR \hat{l}^3 ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. Journal of Clinical Investigation, 2002, 110, 923-932.	8.2	185
189	Biochemical Analysis Using High-Resolution Magic Angle Spinning NMR Spectroscopy Distinguishes Lipoma-Like Well-Differentiated Liposarcoma from Normal Fat. Journal of the American Chemical Society, 2001, 123, 9200-9201.	13.7	54
190	Response to Chemotherapy and Predictors of Survival in Adult Rhabdomyosarcoma. Annals of Surgery, 2001, 234, 215-223.	4.2	132
191	STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene, 2001, 20, 5054-5058.	5.9	643
192	KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors. American Journal of Pathology, 2000, 156, 791-795.	3.8	585
193	Management of soft-tissue sarcomas: an overview and update. Lancet Oncology, The, 2000, 1, 75-85.	10.7	157
194	New diagnostic modalities in soft tissue sarcoma. , 1999, 17, 11-22.		29
195	Classification of human liposarcoma and lipoma using ex vivo proton NMR spectroscopy. Magnetic Resonance in Medicine, 1999, 41, 257-267.	3.0	90
196	Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma., 1999, 86, 1621-1627.		13
197	Long-Term Outcomes After Function-Sparing Surgery Without Radiotherapy for Soft Tissue Sarcoma of the Extremities and Trunk. Journal of Clinical Oncology, 1999, 17, 3252-3259.	1.6	194
198	Adults With Ewing's Sarcoma/Primitive Neuroectodermal Tumor. Annals of Surgery, 1999, 230, 79.	4.2	123

#	Article	IF	Citations
199	Differentiation and reversal of malignant changes in colon cancer through PPARÎ ³ . Nature Medicine, 1998, 4, 1046-1052.	30.7	933
200	Gradient, high-resolution, magic angle spinning 1H nuclear magnetic resonance spectroscopy of intact cells. Magnetic Resonance in Medicine, 1998, 39, 337-345.	3.0	141
201	Terminal Differentiation of Human Breast Cancer through PPARÎ ³ . Molecular Cell, 1998, 1, 465-470.	9.7	779
202	Spindle Cell Rhabdomyosarcoma (So-Called) in Adults. American Journal of Surgical Pathology, 1998, 22, 459-464.	3.7	79
203	Single-Stage, Multimodality Treatment of Soft-Tissue Sarcoma of the Extremity. Annals of Plastic Surgery, 1997, 39, 454-460.	0.9	18
204	Correlation of lipid content and composition with liposarcoma histology and grade. Annals of Surgical Oncology, 1997, 4, 557-563.	1.5	20
205	Gradient, high-resolution, magic-angle spinning nuclear magnetic resonance spectroscopy of human adipocyte tissue. Magnetic Resonance in Medicine, 1997, 38, 399-403.	3.0	124
206	Prognostic Factors Predictive of Survival for Truncal and Retroperitoneal Soft-Tissue Sarcoma. Annals of Surgery, 1995, 221, 185-195.	4.2	251
207	Translocation $t(8;13)(p11;q11-12)$ in stem cell leukemia/lymphoma of t-cell and myeloid lineages. Genes Chromosomes and Cancer, 1995, 12, 148-151.	2.8	23
208	Prognostic Factors Predictive of Survival and Local Recurrence for Extremity Soft Tissue Sarcoma. Annals of Surgery, 1994, 219, 165-173.	4.2	192
209	Long-term Salvageability for Patients With Locally Recurrent Soft-Tissue Sarcomas. Archives of Surgery, 1992, 127, 548.	2.2	58
210	Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). , 0, .		1
211	Feasibility of Preoperative Dose-Painting Intensity Modulated Radiation Therapy (IMRT) for Borderline-Resectable Primary Retroperitoneal Sarcoma. Annals of Surgical Oncology, 0, , .	1.5	1